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Abstract
Background: Fundamental etiologic differences have been suggested to cause earlier onset of breast cancer in less
developed countries (LDCs) than in more developed countries (MDCs). We explored this hypothesis using world-wide
breast cancer incidence data.
Methods: We compared international age-standardized incidence rates (ASR) of pre- (<50 years) and postmenopausal
(≥50 years) breast cancers as well as temporal trends in ASRs of pre-and postmenopausal breast cancer among selected
countries during 1975–2008. We used joinpoint log-linear regression analysis to estimate annual percent changes (APC)
for premenopausal and postmenopausal breast cancer in the northern Europe andi nB l a c ka n dW h i t ew o m e np o p u l a t i o n
in the US.
Results: Premenopausal breast cancers comprised a substantially higher proportion of all incident breast cancers in LDCs
(average 47.3%) compared to MDCs (average 18.5%). However, the ASR of premenopausal breast cancer was consistently
higher in MDCs (29.4/100,000) than LDCs (12.8/100,000). The ASR of postmenopausal cancer was about five-fold higher in
the MDCs (307.6/100,000) than the LDCs (65.4/100,000). The APC of breast cancer in Denmark was substantially higher in
postmenopausal (1.33%) than premenopausal cancer (0.98%). Higher incidence of breast cancer among the white than
black women in the US was pertained only to the postmenopausal cancer.
Conclusion: The substantial and consistent lower age-specific incidence of breast cancer in LDCs than in MDCs contradicts
the theory of earlier onset. Demographic differences with fewer old women in LDCs and lower prevalence of risk factors of
postmenopausal cancer are the most likely explanationt ot h el o w e rm e a na g ea td i a g n o s i si nt h e s ec o u n t r i e s .
Keywords: Breast cancer, Age-standardized rate, Risk factor, Annual percent change, Less developed countries,
Premenopausal
Background
Breast cancer is the most common malignancy among
women and the fifth cause of death due to cancer both in
the less developed (LDCs) and more developed (MDCs)
countries worldwide [1]. However, among women living in
MDCs (except Japan), world-age-standardized incidence
rates (ASR) are still more than 4-fold higher than in LDCs.
In 2008, ASR was estimated to be 89.9 per 100,000
women-years in Western Europe, but only 19.3 in Eastern
Africa [1,2]. Although the incidence rate of breast cancer
has decreased in the US and many other developed
countries since early 2000s [3], it has increased 50-100%
in some Asian countries including India and China during
the last two decades [4,5].
Epidemiologic studies often distinguish premenopausal
from postmenopausal breast cancer [6,7]. Some repro-
ductive risk factors have stronger associations with risk
of postmenopausal breast cancers [8-10] and obesity in-
creases the risk of postmenopausal but decreases the risk
of premenopausal breast cancer [11,12]. Therefore, it is
conceivable that a higher prevalence of known and un-
known causal factors in LCDs could increase chiefly the
incidence of early onset disease.
In LDCs, the average age of women diagnosed with
breast cancer is about 10 years lower than in MDCs
[13-15]. Although the younger age structure of the
population in the LDCs may explain this finding [5,16],
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due to a higher prevalence of risk factors for breast cancer
– such as low parity and late age at first birth in the youn-
ger compared to the older generation [17-19]. In addition,
however, researchers and clinicians have proposed that
earlier onset of breast cancer reflects more fundamental
etiologic differences between women in LDCs and MDCs
that remain to be discovered [14,20-23]. We aimed to in-
vestigate these rival interpretations of the difference in
mean age at diagnosis of breast cancer in LDCs compared
to MDCs.
Methods
We used data published in the GLOBOCAN 2008 by
the International Agency for Research on Cancer (IARC)
to compare the proportion and truncated world age-
standardized rate (ASR) of premenopausal (i.e. <50 years)
and postmenopausal (i.e. ≥50 years) breast cancer in differ-
ent countries in 2008 [24]. Based on GLOBOCAN, we clas-
sified the countries into less developed and more developed.
In each group, we estimated weighted truncated ASR (world
population) for the five countries with the highest coverage
of cancer registration in the latest version of the “Cancer in
Five Continents CI5 Volume IX” [25]. Data from the United
Nations Population Division [26] were used to demonstrate
t h ea g es t r u c t u r ea n dd i f f e r e n c ei nt h ep r o p o r t i o no fw o m e n
aged 20–49 and ≥50 years from total women population (0
to ≥100 years) in the selected countries.
In order to illustrate changes in the incidence rate of
breast cancer over time, we graphed the annual proportions
and ASRs of pre- and postmenopausal breast cancer for
Denmark, Finland, Norway and Sweden because these
countries have had high quality nationwide cancer registra-
tion for more than 50 years. Because the Danish cancer
registry provided the oldest data, we used it to demonstrate
temporal trends in the pre and post-menopausal breast
cancer ratio and ASR from 1943 to 2008 in Denmark. Data
for Denmark, Finland, Norway and Sweden was obtained
from the NORDCAN project (version 5.2) [27].
We also compared temporal trends of pre- and post-
menopausal breast cancer incidences among Black and
White population in the US. Data for the US Black and
White populations was obtained from the Surveillance,
Epidemiology and End Results (SEER) program of the
National Cancer Institute [28].
We hypothesized that the incidence of premenopausal
breast cancer would be stable over time and that changes
in lifestyle factor would mainly affect the postmenopausal
cancers. We used joinpoint log-linear regression analysis
[29] to estimate annual percent changes (APC) for pre-
menopausal and postmenopausal breast cancer. For trend
analysis, the joinpoint regression allows to more accurately
interpret changes over time, and also to determine if those
changes are statistically significant. We used Monte Carlo
permutation test to select the best fitting model. Joinpoint
program (version 4.0) was used for statistical analyses [30].
All ASRs were standardized using the world standard
population [31], and the weights were taken from the popu-
lation distribution of the world standard population. The
age group< 50 years and the age group≥50 years defined
as premenopausal and postmenopausal respectively [32].
Table 1 Estimated proportion and age standardized incidence rate (ASR) of breast cancer per 100,000 women-year in
LDCs and MDCs in 2008 (GLOBOCAN 2008) [24]
Country Overall < 50 years old (premenopausal) ≥ 50 years old (postmenopausal)
Number ASR (W) Number Percent ASR (W) Number Percent ASR (W)
Less developed countries
China 169452 21.6 77449 45.7 12.1 92003 54.3 59.8
India 115251 22.9 55770 48.4 12.2 59481 51.6 65.3
Algeria 4271 28.6 2432 56.9 17 1839 43.1 75.2
Pakistan 19271 31.5 9878 51.3 16.6 9393 48.7 90.7
Egypt 12621 37.3 6152 48.7 20 6469 51.3 106.4
Weighted Average
* 23.3 47.3 12.8 52.7 65.4
More developed countries
Germany 64147 81.7 11289 17.6 28.8 52858 84.4 293.6
Canada 22986 83.2 4232 18.4 26 18754 81.6 311.9
Australia 13384 84.7 2877 21.5 30 10507 78.5 303.7
United Kingdom 46458 89.1 8866 19.1 31.7 37592 80.9 318.7
Denmark 4696 101.1 748 15.9 31.5 3948 84.1 379.4
Weighted Average 85.1 18.5 29.4 81.5 307.6
*The weights were taken from population distribution of the world standard population.
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The proportion of all breast cancer cases diagnosed before
age 50 was substantially higher (47.3% in average) among
the LDCs compared to the MDCs (18.5% in average). Specif-
ically, 45.7%, 48.4% and 56.9% of breast cancer patients were
diagnosed before age 50 in China, India and Algeria, whilst
corresponding proportions were 21.5%, 19.1% and 15.9% in
Australia, UK and Denmark. However, the average ASR for
premenopausal breast cancer was lower in the LDCs (12.8
per 100,000) compared to the MDCs (29.4 per 100,000). Par-
ticularly, ASRs of premenopausal breast cancer were 12.1,
12.2 and 17 per 100,000 in China, India and Algeria, while
Figure 2 Estimated proportion of Women population in age groups 20–49 and ≥50 from total women population in selected countries
in 2005 (United Nations 2012) [26].
Figure 1 Estimated proportions and age standardized incidence rate (ASR) of pre- and postmenopausal breast cancer on a log scale
for selected countries in 2008 (GLOBOCAN 2008) [16].
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30, 31.7 and 31.5 per 100,000 respectively (Table 1).
The age-specific incidence rate of premenopausal breast
cancer was almost similar in the LDCs and MDCs, being
slightly higher in MDCs. However, incidence rate of post-
menopausal breast cancer was substantially higher in the
MDCs compared to the LDCs (Figure 1). The proportion
of postmenopausal women was higher in MDCs com-
pared to LDCs (Figure 2).
We found a dramatic increase in the ASR of postmen-
opausal compared to premenopausal breast cancer in
Denmark from 1943 to 2008 (Figure 3). The annual per-
centage change for postmenopausal cancer was 1.33%
(Table 2), and ASR increased 155% from 149.8 in 1943
to 382.4 per 100,000 in 2008. During the same period
premenopausal breast cancer increased 91% from 15.3
per 100,000 in 1943 to 29.2 per 100,000 in 2008
(APC 0.98). Meanwhile, the proportion of premeno-
pausal to all breast cancers decreased from 29% to
16% (APC −0.74).
Although the incidence rates of premenopausal breast
cancer increased slightly in all selected countries from
1975 through 2008, more significant changes happened
in postmenopausal breast cancer incidence rate over
time (Table 3). Furthermore, difference in the incidence
rate of breast cancer between countries was considerable
for postmenopausal breast cancer (Figure 4). Likewise,
the difference in the risk of breast cancer among the
black and white women pertained only to the post-
menopausal women and the incidence of premeno-
pausal women was equally low among them from
1975 to 2008.
Discussion
We showed that the incidence rate of premenopausal
breast cancer in the LDCs is indeed invariably lower
than that in the MDCs. However, the proportion of pre-
menopausal breast cancer from total breast cancers is sub-
stantially higher in these countries compared to MDCs. In
addition, our findings reveal that the global variation and
increase in the incidence rate pertains mostly to postmen-
opausal breast cancers.
In LDCs, the majority of breast cancers occur among
premenopausal women and the mean age of patients is
Table 2 Annual percent change (APC) with 95%
confidence intervals (CIs) in ASRs and proportion of
premenopausal and ASR of postmenopausal breast
cancer in Denmark from 1943 to 2008
Premenopausal (< 50 years) Postmenopausal (≥ 50 years)
Period APC (95% CI) Period APC (95% CI)
ASR*
1943 – 1986 1.54 (1.36 to 1.72) 1943 – 1958 0.18 (-0.42 to 0.78)
1986 – 2008 -0.10 (-0.47 to 0.26) 1958 – 1985 1.45 (1.18 to 1.71)
AAPC** 0.98 (0.81 to 1.15) 1985 – 2008 1.97 (1.64 to 2.29)
AAPC 1.33 (1.13 to 1.54)
Proportion***
1943 – 1978 -1.04 (-1.21 to -0.88) 1943 – 1978 0.35 (0.30 to 0.41)
1978 – 1988 1.48 (0.19 to 2.79) 1978 – 1988 -0.44 (-0.87 to -0.01)
1988 – 2008 -2.04 (-2.42 to -0.64) 1988 – 2008 0.54 (0.41 to 0.67)
AAPC -0.74 (-0.84 to -0.64) AAPC 0.29 (0.21 to 0.37)
*Age standardized incidence rate adjusted to the world standard population.
**Average annual percent change from 1943 to 2008.
***Proportion from total number of invasive breast cancers.
Figure 3 Premenopausal and postmenopausal breast cancer age standardized incidence rate (ASRs) and percent of premenopausal
patients in Denmark from 1943 to 2008.
Ghiasvand et al. BMC Cancer 2014, 14:343 Page 4 of 8
http://www.biomedcentral.com/1471-2407/14/343around 50 years. Some investigators have concluded that
breast cancer occurs about one decade earlier in several
populations including Iran [23], Mexico [14], Africa [20]
and blacks in the UK [21]. Some have also suggested the
existence of specific genetic and environmental risk fac-
tors in LDCs [4,14] which would call for specific preven-
tion and early detection strategies in these countries
such as starting mammography screening already at age
40 [13]. However, these conclusions were based on com-
parison of median age and proportion of breast cancer
in different age groups rather than a comparison of age-
specific incidence rates in LDCs and MDCs.
International variations in coverage and accuracy of
cancer registries and diagnostic/screening strategies
might explain part of the dramatic difference in the inci-
dence rate of postmenopausal breast cancer worldwide.
About one fourth of postmenopausal breast cancer in
MDCs with national mammography screening is attrib-
uted to overdiagnosis [33,34]. In a comparative study be-
tween Sweden and Singapore, both with nationwide
Table 3 Annual percent change (APC) with 95% confidence intervals (CIs) in premenopausal (< 50) and
postmenopausal (≥ 50) breast cancer age standardized incidence rate (ASRs), estimated with the best-fitting
joinpoint model
Country
Postmenopausal (≥ 50) Premenopausal (< 50)
Period APC
* (95% CI) Period APC
* (95% CI)
Denmark
1975 – 1980 -1.23 (-4.00 to 1.63) 1975 – 2008 0.25 (0.05 to 0.46)
**
1980 – 2008 2.01 (1.80 to 2.23)
**
Sweden
1975 – 1979 3.00 (1.44 to 4.59)
** 1975 – 2008 0.94 (0.79 to 1.10)
**
1979 – 1985 -1.10 (-2.17 to -0.03
**
1985 – 1990 5.82 (4.22 to 7.45)
**
1990 – 1993 -2.36 (-6.96 to 2.47)
1993 – 2002 2.63 (2.09 to 3.17)
**
2002 – 2008 -1.30 (-2.10 to -0.49)
**
Finland
1975 – 1984 2.32 (1.51 to 3.13)
** 1975 – 1998 2.48 (2.18 to 2.77)
**
1984 – 1988 6.26 (1.75 to 10.96)
** 1998 – 2008 -1.20 (-2.19 to -0.19)
**
1988 – 2008 2.24 (2.00 to 2.84)
**
Norway
1975 – 2003 0.62 (0.30 to 0.94)
** 1975 – 2008 0.96 (0.77 to 1.16)
**
1993 – 1997 8.08 (2.83 to 13.60)
**
1997 – 2003 2.24 (-0.01 to 4.55)
2003 – 2008 -2.21 (-4.37 to -0.01)
**
US (whites)
1975 – 1982 0.89 (0.15 to 1.64)
** 1975 – 1980 -1.09 (-2.48 to 0.32)
1982 – 1987 5.54 (3.70 to 7.41)
** 1980 – 1986 2.63 (1.18 to 4.09)
**
1987 – 1993 -0.27 (-1.50 to 0.98) 1986 – 2008 -0.07 (-0.22 to 0.08)
1993 – 2000 1.69 (0.74 to 2.65)
**
2000 – 2004 -3.79 (-6.42 to -1.08)
**
2004 – 2008 -0.17 (-1.91 to 1.60)
US (blacks)
1975 – 1978 -2.65 (-9.10 to 4.26) 1975 – 1991 1.32 (0.72 to 1.92)
**
1978 – 1986 4.64 (2.74 to 6.58)
** 1991 – 2008 -0.43 (-0.97 to 0.12)
1986 – 2008 0.67 (0.34 to 1.00)
**
*The model was specified to include a maximum of six joinpoits. The model constrained the joinpoints to be at least five years from each other (to be more
conservative) and from the boundaries of the total study period.
**Statistically significant annual percent changes are printed in bold.
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was shown to be unrelated to differences in registration
systems. Hence, cohort effects due to changes in lifestyle
and reproductive factors in these countries as well as the
screening impact need to be taken into account [18,35].
Variations in lifestyle and reproductive risk factors seem
to play a more important role in the global differences
in the incidence of postmenopausal breast cancer. In
several studies [19,35-37], the increasing incidence of
breast cancer follows changes in the reproductive and
lifestyle factors.
Some established risk factors including age at menar-
che and age at menopause, include hormonal mecha-
nisms, which are involved in the development of breast
cancer [38]. Estrogen receptor (ER), progesterone recep-
tor (PR), and human epidermal growth factor receptor 2
(HER2), are the tumor markers that have been widely
studied in relation to the etiology, prognosis and treat-
ment of breast cancer subtypes [8,38,39]. Some epi-
demiological studies have reported heterogeneity of
breast cancer risk factors with hormone receptors and
the expression of HER2 [40]. Reproductive factors and
BMI were shown to be associated with ER +and PR +
breast cancer, compared with ER- and PR- tumors
[8,41]. The prevalence of hormone receptor negative
cancer is higher among premenopausal women than
among postmenopausal women, while ER +and PR +
breast cancer in more prevalent after menopause and its
incidence increases with age [42,43].
The relatively stable incidence rate of premenopausal
breast cancer during several decades [44,45] suggest a
predominant role of genetic and constant environmental
risk factors. Moreover, several studies showed that only
postmenopausal breast cancer risk increased among
women who moved from low risk to high-risk countries
[10,46-48]. In a recent study among migrant women in
Sweden, risk of breast cancer increased only at postmen-
opausal ages [10]. A study of migration history and risk
of breast cancer showed a significant increase in the
trend of postmenopausal breast cancer risk in the sec-
ond and third generation of Hispanic immigrants, but
not in premenopausal breast cancer, after adjusting for
lifestyle and reproductive factors [49]. In addition, a
study of racial/ethnic differences in the incidence of
postmenopausal breast cancer in the Women’s Health
Initiative revealed significant ethnic differences, with
lower incidence among Asian/Pacific Islanders, African
American and Hispanics compared with Whites. How-
ever, after adjustment for established risk factors, the ob-
served differences were attenuated and statistically not
significant [45].
Conclusions
The global variation in the incidence rate of breast can-
cer is due chiefly to the differences in the risk of post-
menopausal breast cancer and variation in exposure to
the reproductive and lifestyle risk factors. Aging of the
population and adaptation of western lifestyle in the
LDCs would soon lead to a higher incidence of breast
cancer in these countries. While the prevention and pol-
icy making at the time being should be focused on the
bulk of young breast cancer patients in LDCs, it is es-
sential to take a closer look and monitor the transition
to higher incidence of postmenopausal breast cancer in
the future and adapt the preventive and cancer control
policies accordingly.
Figure 4 Trend of pre- and postmenopausal incidence rates of breast cancer during 1975 to 2008. Rates are age-adjusted to the world
standard population. Sources: [27,28].
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